Last reviewed · How we verify
NCT05362539
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria
NA trial testing Cystoscopy in Bladder Cancer in 246 participants. Completed in 1 April 2022.
1 June 2021
Quick facts
| Lead sponsor | Mansoura University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 246 |
| Start date | 1 February 2019 |
| Primary completion | 1 June 2021 |
| Estimated completion | 1 April 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Cystoscopy
- Computed tomography
- DNA hypermethylation assay
- Urine cytology
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
Mansoura University
Who can join
18 and older, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The current study aimed to assess the diagnostic performance of novel urine-based DNA hypermethylation of six genes (GATA4, P16, P14, APC, CDH1 and CD99) for UBC detection in patients with hematuria.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05362539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cystoscopy
Trials testing the same drug.
- NCT07061964 — Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva · Phase 2 · recruiting
- NCT07000084 — Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Inva · Phase 3 · recruiting
- NCT06704191 — In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial · Phase 1, PHASE2 · recruiting
- NCT06725212 — Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia · NA · recruiting
- NCT05987241 — Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo · Phase 2, PHASE3 · recruiting
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other Mansoura University trials
Trials by the same sponsor.
- NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
- NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
- NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
- NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05362539 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mansoura University
- Last refreshed: 5 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05362539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing